Olumacostat | CAS#54857-86-2

MedKoo Cat#: 125555 | Name: Olumacostat

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Olumacostat has a role as an EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor, a PPARalpha agonist, an antineoplastic agent and an apoptosis inducer.

Chemical Structure

Olumacostat

CAS#54857-86-2

Theoretical Analysis

MedKoo Cat#: 125555

Name: Olumacostat

CAS#: 54857-86-2

Chemical Formula: C19H32O4

Exact Mass: 324.2300

Molecular Weight: 324.46

Elemental Analysis: C, 70.33; H, 9.94; O, 19.72

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

TOFA; 54857-86-2; 5-(Tetradecyloxy)-2-furoic acid; Olumacostat; 5-Tetradecyloxy-2-furonic acid

IUPAC/Chemical Name

5-(tetradecyloxy)furan-2-carboxylic acid

InChi Key

CZRCFAOMWRAFIC-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H32O4/c1-2-3-4-5-6-7-8-9-10-11-12-13-16-22-18-15-14-17(23-18)19(20)21/h14-15H,2-13,16H2,1H3,(H,20,21)

SMILES Code

CCCCCCCCCCCCCCOC1=CC=C(O1)C(O)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 324.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: He D, Sun X, Yang H, Li X, Yang D. TOFA induces cell cycle arrest and apoptosis in ACHN and 786-O cells through inhibiting PI3K/Akt/mTOR pathway. J Cancer. 2018 Jun 23;9(15):2734-2742. doi: 10.7150/jca.26374. PMID: 30087714; PMCID: PMC6072807. 2: Liu X, Jiang Q, Lv J, Yang S, Huang Z, Duan R, Tao T, Li Z, Ju R, Zheng Y, Su W. Insights gained from single-cell analysis of immune cells in tofacitinib treatment of Vogt-Koyanagi-Harada disease. JCI Insight. 2022 Dec 8;7(23):e162335. doi: 10.1172/jci.insight.162335. PMID: 36301664; PMCID: PMC9746911. 3: Li S, Qiu L, Wu B, Shen H, Zhu J, Zhou L, Gu L, Di W. TOFA suppresses ovarian cancer cell growth in vitro and in vivo. Mol Med Rep. 2013 Aug;8(2):373-8. doi: 10.3892/mmr.2013.1505. Epub 2013 May 31. PMID: 23732836. 4: Kleinrensink NJ, Perton FT, Pouw JN, Vincken NLA, Hartgring SAY, Jansen MP, Arbabi S, Foppen W, de Jong PA, Tekstra J, Leijten EFA, Spierings J, Lafeber FPJG, Welsing PMJ, Heijstek MW; TOFA-PREDICT author group. TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA). BMJ Open. 2022 Oct 10;12(10):e064338. doi: 10.1136/bmjopen-2022-064338. PMID: 36216430; PMCID: PMC9557317.